A Phase 1 interventional study of Olatorepatide in adults living with overweight or obesity without diabetes

Study Description

A clinical study testing a new injectable weight loss medication called Olatorepatide to evaluate its safety, tolerability, and effectiveness in adults who are overweight or obese but do not have diabetes

Study Details

Registry ID:

NCT07685808

Conditions:

Overweight or Obesity

Phase:

Phase 2

Target Enrollment:

360 participants

Start Date:

July 28, 2026

Age Range:

18–999 years

Healthy Volunteers:

No

Study Locations (5 sites)

• Clinical Site Partners, LLC DBA Flourish Research
  Winter Park, FloridaUnited States, United States
• K2 Medical Research Maitland LLC, Main Office
  Maitland, FloridaUnited States, United States
• Charter Research LLC - The Villages
  The Villages, FloridaUnited States, United States
• AMR Clinical - Lexington
  Lexington, KentuckyUnited States, United States
• Diablo Clinical Research - Flourish Research
  Walnut Creek, CaliforniaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →